Deals this week: Becton Dickinson Holdings, Terumo BCT, Royal Philips

23 June 2016 (Last Updated June 23rd, 2016 18:30)

Becton Dickinson Holdings (BD) has announced the signing of a research agreement with Singapore Immunology Network (SigN). Through the partnership, the companies intend to achieve advancements in immunology research by improving existing cell analysis technologies.

Becton Dickinson Holdings (BD) has announced the signing of a research agreement with Singapore Immunology Network (SigN).

Through the partnership, the companies intend to achieve advancements in immunology research by improving existing cell analysis technologies.

Pursuant with the agreement, BD will provide its novel Horizon Brilliant reagents and FACSymphony, a state-of-the-art flow cytometer, to SIgN, which will employ them in its ongoing research on age-related loss of immunity in the elderly suffering from various acute and chronic conditions.

Washington-based pharmacy kit processing software start-up, Kit Check has announced a $15m Series C financing round.

"Washington-based pharmacy kit processing software start-up, Kit Check has announced a $15m Series C financing round."

Led by Baxter Ventures, the financing round saw the participation of previous investors including Kaiser Permanente Ventures, Rex Health Ventures, New Leaf Venture Partners, Easton Capital Investment Group, LionBird, Sands Capital Ventures and a new investor named Black Granite Capital.

The tech-company, which provides cloud-based software (SaaS) and Internet of Things (IoT), will use the proceeds to increase its market share and extend its solutions to automate new hospital processes.

Terumo BCT, a medical device company, has announced that it has received an initial funding of $17.4m from Biomedical Advanced Research and Development Authority (BARDA) to initiate the Mirasol platelets in plasma clinical trial (MIPLATE), using its Mirasol Pathogen Reduction Technology (PRT) system in the US.

The MIPLATE trial, which requires a total funding of $169m over a 10-year period, is a multi-centre study designed to evaluate the clinical effectiveness of standard platelets in plasma compared to the Mirasol-treated platelets in plasma in patients with hypoproliferative thrombocytopenia.

Royal Philips has announced its collaboration with Visiopharm to provide digital pathology solutions that help pathologists with an objective diagnosis of breast cancer.

The companies have signed a licensing agreement, according to which they will offer breast cancer panel software algorithms with Philips IntelliSite digital pathology solution.

Waters Corporation, an advanced analytical and material science technologies developer, has partnered with Bioprocessing Technology Institute (BTI) for the development of new therapeutic strategies to recognise cancer markers and probe cancer biology.

Through the new collaboration, the companies will develop a glycosphingolipid (GSL) head group database containing glucose unit (GU) retention times and collision cross-section (CCS) values to compile an experimental library for disease-related GSL glycans together with a glycan / MS spectral library.